The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity

Senicapoc, a Gardos channel inhibitor, prevented erythrocyte dehydration in clinical trials of patients with sickle cell disease. We tested the hypothesis that senicapoc-induced blockade of the Gardos channel inhibits Plasmodium growth. Senicapoc inhibited in vitro growth of human and primate plasmo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Main Authors: Tubman, Venée N., Mejia, Pedro, Shmukler, Boris E., Bei, Amy K., Alper, Seth L., Mitchell, James R., Brugnara, Carlo, Duraisingh, Manoj T.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2015
Assuntos:
Clinical Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704178/
https://ncbi.nlm.nih.gov/pubmed/26459896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01668-15
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares